✦ LIBER ✦

A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923

✍ Scribed by A. Hamilton; D. Larsimont; R. Paridaens; M. Drijkoningen; M. van de Vijver; P. Bruning; A. Hanby; S. Houston; I. Treilleux; J.P. Guastalla; A. Van Vreckem; R. Sylvester; M. Piccart

Book ID: 119991303
Publisher: CIG Media Group, LP.
Year: 2000
Tongue: English
Weight: 126 KB
Volume: 1
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2000.n.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Commentary on “A Study of the Value of p

Commentary on “A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923”

✍ Vered Stearns; Daniel F. Hayes 📂 Article 📅 2000 🏛 CIG Media Group, LP. 🌐 English ⚖ 53 KB

Is ERBB-2 A predictive marker for respon

Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

✍ P. De Crémoux; V. Diéras; V. Le Doussal; A. Vincent-Salomon; M. Tubiana-Hulin; J 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB

The response of advanced pancreatic canc

The response of advanced pancreatic cancer (APC) to gemcitabine monochemotherapy in relation to the expression of proliferation markers, oncogenes Her-2, Bcl-2, C-myc and p53 antioncogene. A retrospective clinico-pathological study

✍ P. Karasek; R. Nenutil; B. Vojtesek; R. Vyzula 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Clinical response after two cycles compa

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

✍ Gunter von Minckwitz, Hans-Peter Sinn, Günter Raab, Sibylle Loibl… 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 179 KB

1141 Clinical Use of HER2 Extracellular

1141 Clinical Use of HER2 Extracellular Domain as a Marker to Monitor Cancer Status and Predict the Response to Anti-cancer Treatment in Breast Cancer

✍ Kontani, K.; Hashimoto, S.; Murazawa, C.; Ohtani, M.; Date, M.; Yamauchi, A.; Yo 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Use of neuroendocrine markers, p53, and

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study

✍ Graziano, Stephen L; Tatum, Arthur; Herndon, James E; Box, James; Memoli, Vincen 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 88 KB